title: Human development index is associated with mortality-to-incidence ratios of gastrointestinal cancers.
abstract: OBJECTIVE
  To identify the role of human development in the incidence and mortality rates of gastrointestinal cancers worldwide.
  
  
  METHODS
  The age-standardized incidence and mortality rates for gastrointestinal cancers, including cancers of the esophagus, stomach, pancreas, liver, gallbladder, and colorectum, were obtained from the GLOBOCAN 2008 database and United States Cancer Statistics (USCS) report. The human development index (HDI) data were calculated according to the 2011 Human Development Report. We estimated the mortality-to-incidence ratios (MIRs) at the regional and national levels, and explored the association of the MIR with development levels as measured by the HDI using a modified "drug dose to inhibition response" model. Furthermore, countries were divided into four groups according to the HDI distribution, and the MIRs of the four HDI groups were compared by one-way ANOVA followed by the Tukey-Kramer post-hoc test. State-specific MIRs in the United States were predicted from the estimated HDI using the fitted non-linear model, and were compared with the actual MIRs calculated from data in the USCS report.
  
  
  RESULTS
  The worldwide incidence and mortality rates of gastrointestinal cancers were as high as 39.4 and 54.9 cases per 100000 individuals, respectively. Linear and non-linear regression analyses revealed an inverse correlation between the MIR of gastrointestinal cancers and the HDI at the regional and national levels (β < 0; P = 0.0028 for regional level and < 0.0001 for national level, ANOVA). The MIR differed significantly among the four HDI areas (very high HDI, 0.620 ± 0.033; high HDI, 0.807 ± 0.018; medium HDI, 0.857 ± 0.021; low HDI, 0.953 ± 0.011; P < 0.001, one-way ANOVA). Prediction of the MIRs for individual United States states using best-fitted non-linear models showed little deviation from the actual MIRs in the United States. Except for 28 data points (9.93% of 282), the actual MIRs of all gastrointestinal cancers were mostly located in the prediction intervals via the best-fit non-linear regression models.
  
  
  CONCLUSIONS
  The inverse correlation between HDI and MIR demonstrates that more developed areas have a relatively efficacious healthcare system, resulting in low MIRs, and HDI can be used to estimate the MIR.
authors: Department of Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China.
authors: Qi-Da
authors: QD
authors: Hu
authors: Qi
authors: Q
authors: Zhang
authors: Wei
authors: W
authors: Chen
authors: Xue-Li
authors: XL
authors: Bai
authors: Ting-Bo
authors: TB
authors: Liang
mesh_terms: D017677:Age Distribution; D000367:Age Factors; D000704:Analysis of Variance; D005770:Gastrointestinal Neoplasms / Q000453:epidemiology* / Q000401:mortality; D054625:Healthcare Disparities; D006803:Human Development; D006801:Humans; D015994:Incidence; D016014:Linear Models; D017711:Nonlinear Dynamics; D012111:Residence Characteristics
keywords: Gastrointestinal neoplasms; Healthcare disparities; Human development index; Mortality-to-incidence ratio; Socioeconomic factors
references: Med Care. 2002 Jan;40(1):52-9
references: 11748426
references: J Clin Oncol. 2006 May 10;24(14):2204-8
references: 16682740
references: Cancer. 2009 Jun 1;115(11):2539-52
references: 19296515
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Lancet Oncol. 2012 May;13(5):447-8
references: 22554538
references: Gastroenterology. 2010 Jun;138(6):2115-26
references: 20167216
references: J Hepatol. 2006 Oct;45(4):529-38
references: 16879891
references: Soc Sci Med. 2013 May;85:38-42
references: 23540364
references: J Urol. 2012 Jun;187(6):1978-83
references: 22498216
references: Am J Public Health. 2010 Apr 1;100 Suppl 1:S186-96
references: 20147693
references: JAMA. 2000 May 17;283(19):2579-84
references: 10815125
references: J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94
references: 19033571
references: Eur J Public Health. 2011 Oct;21(5):573-7
references: 20813895
references: N Engl J Med. 2001 Sep 13;345(11):784-9
references: 11556297
references: Lancet. 2010 Oct 2;376(9747):1186-93
references: 20709386
references: Annu Rev Public Health. 2011;32:381-98
references: 21091195
references: Public Health Rep. 2003 Jul-Aug;118(4):293-302
references: 12815076
references: Aliment Pharmacol Ther. 2003 Nov;18 Suppl 3:7-30
references: 14531737
references: Lancet. 2005 Nov 19;366(9499):1784-93
references: 16298215
references: Am J Public Health. 2005 Apr;95(4):553-5
references: 15798106
references: Lancet Oncol. 2012 Aug;13(8):790-801
references: 22658655
references: Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
references: 20647400
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: BMJ. 2003 Feb 15;326(7385):368
references: 12586671
references: Aliment Pharmacol Ther. 2013 May;37(10):963-8
references: 23550618
references: Control Clin Trials. 1998 Dec;19(6):589-601
references: 9875838
references: Lancet. 2013 Feb 9;381(9865):427-9
references: 23388076